pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-7515 |
Genomic Coordinates | chr2: 6650373 - 6650439 |
Description | Homo sapiens miR-7515 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-7515 | |||||||||||||||||||||||||||
Sequence | 46| AGAAGGGAAGAUGGUGAC |63 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Cloned | |||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | CNNM4 | ||||||||||||||||||||
Synonyms | ACDP4 | ||||||||||||||||||||
Description | cyclin and CBS domain divalent metal cation transport mediator 4 | ||||||||||||||||||||
Transcript | NM_020184 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on CNNM4 | |||||||||||||||||||||
3'UTR of CNNM4 (miRNA target sites are highlighted) |
>CNNM4|NM_020184|3'UTR 1 CAGGAGGGCCCGGGGCCCCCTGCCCACCCTGCGGGGGCCTCCCCAGTGGGCCCACATGAAGAGAGGGAACCTGTTAGTCC 81 AGAAAGGATACGGATAGATAGCCTGTCTGACTGAACAGCCAGATGGCCCCCAGCCTATGGGGGATCTGGCCTCTGCCAGG 161 GACCTCTGAGTAGCTCTGAGGTGGCACTGTCCAGCCCTGGATAGGGGGGGCAGTGGGCCAGCTACCGTAAGCAAAGGCTG 241 TTTTTTACTGAGAGAATTTCTAAAGTAGGCTCATCACTTTTTTTTAAATATCATTTTGGGAAGGGAAGACAGGGTTAAGG 321 AACTTTATTTAAAAAAAAAATATTTTTTTCCTAAAAACTATAAAAGAGGAAGGGTTTCTTGTCCCGGGAAGCAACGGACA 401 TAATCTGTTCCCAGCCATGGCCTTCCAGCTTGTGTCCCTGATTCAGGGAGCTCTCCCTTCCTCCTCCTCCTCCTCCTCCG 481 GAGGTGGGATCCCAGAGCCTGCCAGTGGAGGCTTATCTGTTGGGAGGAAGACAGCTCTTCACAGAAGCAAAGAACAAAAT 561 GGCATGGAGATCAGCTGCCTGAGCACCTGCGCTGTAGCTTATCTGACAACGCTGAGGCCACGAGCTCCTGGGTAGCTGTG 641 ATCAGGGACATGATAATCTGAGCTATGCAGAGGAGCACATCTGTTGTCAACTGCTGTACCCAGAAATCTAGAACTCTGCC 721 GACAGCCTCTCCTGGTGAGTCGGGACTCAGCTGAGGACACATCCCCACCCTGCCTCCCATCTGGCCCTTTGGACAACTGG 801 CCCTTTGTGACAGGGCTGACTCAAGTGTTAGGCAGGGTCTCAGGCCTTTGATTGCTCACCCCTGCTCCCCAGGCCCTGCC 881 CTCACTTTTACCAAAGGTTCTCCCTCGGCGGGAGGGCATCTGTGTTGGAGGTGATTTGTCTGGGTTCTTCCTTTTGGTTC 961 CAGAAGGAACTGTCAGTCATCAGCATCTGCGTTGTTAGCAGTCAGTACCACCCCCGCCCCACAATGACAGTCAAGGCTGA 1041 CTTGTTGACTGAAGCCTTTTTCCCAGACCCCTTATTTCGAATCCCCAAGCTTCAGTCCCTCTTGGGGGTGGAGACAAGAG 1121 GACATGTGGGAAGCCACGGAAGCAGGTTCTTTATGTCCTCTCCTCTGTGGCTGGCAAGGCTCACCTGGCCTTATCCACCC 1201 ACTTATGGAACCTCAGGAGAGGAGGGCTCCTCCTAAAGGCATGCAGCTTGCAGCCCCTCTTTCTCACACGTGTGATCCTA 1281 GCGTGAGAGGTCATCCTGCCCTTGCTGAAGTTAGTAGTACTGTACTAAGAGCTCTGCCCTCATGTGAATTCCTGCCCTGG 1361 CGCCTCTTCCCTGGGGCTGAATCAGGCCCTGCTGCAAAACTCCAGGCTTCCCAGGGTTGGGGAGGCTGTGGGACCAAGGT 1441 CCATGTTGGTCCTTCCACTGGGTGCAGCAGGAGCTGGGTCCCGAGAGCCTGGCAGGTGAAACTCTGCAGGCCTTCCGCCT 1521 GATTATTATTTATTCACTCCTTTCCTCACCCCAAGTGCCCTGCTCTCCAGGTGCCTAGAGTATCCTAACTCTTAGGACCA 1601 GGGATTGTCTTGCACCAAGTATGCCTACCCCTGGCCAGTCTGAGGTCTCCTAGCCATAGAACTGACTCCTGGAAGCCTGG 1681 AGAGAAGGTGGTGACACCCATGGGTTCTCAACTGTAAGGAAAAAAGACACCAGACTTTTGTTCCCTAGTGGGGGAAAGCC 1761 CTTAGTCTTGTACAGGAGCAGCTTGCTCCCAAGTCCTTTTGGAAGCTGGCAGAGCTATATTCCTGACAGCCCTGACTGCC 1841 AGGTAGAGCAAAAGACATTGGTGGGGGTATGTGAAGCAAAAGGGGCAGGTGCACACACCTCCACAGTGACCTCTGTGCAC 1921 ACGGTTACCACCAACTGGCTGGCCCTCCTCCTCTTCCCTGGCCCATTGATCATCCCTTCTCACAGAGGGTCATCATTATT 2001 TCCAAATATTGTTTGTCTGATGACTTCCTCTTCCCAGTGCAATTTTTCCCTTCCTATTTCAACCTCTGGTTCCTGGGATG 2081 AGCCATACCCTGGAACTGGCCCACCCACTGTGTCTTCCACGTAAGGGAGACCTTTGCAAAGGGCATCCAAATGGGTAGGC 2161 AGGTGACAGCCGCCGTATTTATTTTGCATAATATTTTAATTTGTATATTTTTGTGATTTATTTTGGCGTTATGAGTTTGA 2241 CTCTCGGGGAGTTTTGTTGTTATGACTCTTGTGTCTTTTGTCACAAAACAATGATATTTGCTAAACGATATATGGAATTT 2321 ATTTTTGATTGGTAATAAAAAATCAAATATGTATAAATCCTGGTGAATCTACAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Disease | 26504.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM714645. RNA binding protein: AGO2. Condition:completeT1
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | C8166 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462572. RNA binding protein: AGO2. Condition:C8166 NL4-3
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM714645 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repB |
Location of target site | ENST00000540067.1 | 3UTR | CAAUUUUUCCCUUCCUAUUUCAACCUCUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1462572 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | C8166 / C8166 NL4-3 |
Location of target site | ENST00000540067.1 | 3UTR | CCUUCCUCCUCCUCCUCCUCCUCCGG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
116 hsa-miR-7515 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT063460 | SKI | SKI proto-oncogene | 2 | 4 | ||||||||
MIRT089615 | MAT2A | methionine adenosyltransferase 2A | 2 | 10 | ||||||||
MIRT100238 | PRR3 | proline rich 3 | 2 | 4 | ||||||||
MIRT159239 | NRBP1 | nuclear receptor binding protein 1 | 2 | 2 | ||||||||
MIRT183526 | BTG2 | BTG anti-proliferation factor 2 | 2 | 2 | ||||||||
MIRT266866 | SLC25A44 | solute carrier family 25 member 44 | 2 | 2 | ||||||||
MIRT304116 | CNNM4 | cyclin and CBS domain divalent metal cation transport mediator 4 | 2 | 4 | ||||||||
MIRT331077 | EIF5AL1 | eukaryotic translation initiation factor 5A-like 1 | 2 | 2 | ||||||||
MIRT350659 | PDIA6 | protein disulfide isomerase family A member 6 | 2 | 2 | ||||||||
MIRT438442 | MET | MET proto-oncogene, receptor tyrosine kinase | 3 | 1 | ||||||||
MIRT443555 | ZFP3 | ZFP3 zinc finger protein | 2 | 2 | ||||||||
MIRT447969 | MSH6 | mutS homolog 6 | 2 | 2 | ||||||||
MIRT448635 | ONECUT1 | one cut homeobox 1 | 2 | 2 | ||||||||
MIRT451778 | USP36 | ubiquitin specific peptidase 36 | 2 | 2 | ||||||||
MIRT452615 | REPIN1 | replication initiator 1 | 2 | 2 | ||||||||
MIRT453433 | GLG1 | golgi glycoprotein 1 | 2 | 2 | ||||||||
MIRT454015 | ALKBH5 | alkB homolog 5, RNA demethylase | 2 | 2 | ||||||||
MIRT454961 | TPM2 | tropomyosin 2 | 2 | 2 | ||||||||
MIRT455364 | KDM5C | lysine demethylase 5C | 2 | 2 | ||||||||
MIRT455434 | ID3 | inhibitor of DNA binding 3, HLH protein | 2 | 2 | ||||||||
MIRT455456 | EPB41L4B | erythrocyte membrane protein band 4.1 like 4B | 2 | 2 | ||||||||
MIRT455595 | TAF12 | TATA-box binding protein associated factor 12 | 2 | 2 | ||||||||
MIRT455689 | GLO1 | glyoxalase I | 2 | 2 | ||||||||
MIRT455949 | CYP4A22 | cytochrome P450 family 4 subfamily A member 22 | 2 | 2 | ||||||||
MIRT456135 | SAMD10 | sterile alpha motif domain containing 10 | 2 | 2 | ||||||||
MIRT456821 | PIGP | phosphatidylinositol glycan anchor biosynthesis class P | 2 | 2 | ||||||||
MIRT457441 | NOL10 | nucleolar protein 10 | 2 | 2 | ||||||||
MIRT458048 | TSEN54 | tRNA splicing endonuclease subunit 54 | 2 | 2 | ||||||||
MIRT458237 | NXPH3 | neurexophilin 3 | 2 | 2 | ||||||||
MIRT458671 | GPR35 | G protein-coupled receptor 35 | 2 | 2 | ||||||||
MIRT458741 | CES2 | carboxylesterase 2 | 2 | 2 | ||||||||
MIRT459102 | CYP4A11 | cytochrome P450 family 4 subfamily A member 11 | 2 | 2 | ||||||||
MIRT459676 | VPS37C | VPS37C, ESCRT-I subunit | 2 | 2 | ||||||||
MIRT459776 | IDH3A | isocitrate dehydrogenase 3 (NAD(+)) alpha | 2 | 2 | ||||||||
MIRT461975 | PACSIN1 | protein kinase C and casein kinase substrate in neurons 1 | 2 | 2 | ||||||||
MIRT462267 | TPI1 | triosephosphate isomerase 1 | 2 | 2 | ||||||||
MIRT463296 | ZFP91 | ZFP91 zinc finger protein | 2 | 2 | ||||||||
MIRT463446 | ZC3HAV1L | zinc finger CCCH-type containing, antiviral 1 like | 2 | 2 | ||||||||
MIRT464379 | URM1 | ubiquitin related modifier 1 | 2 | 2 | ||||||||
MIRT465552 | TOB2 | transducer of ERBB2, 2 | 2 | 2 | ||||||||
MIRT467359 | SP2 | Sp2 transcription factor | 2 | 2 | ||||||||
MIRT467638 | SLC7A5 | solute carrier family 7 member 5 | 2 | 2 | ||||||||
MIRT467795 | SLC2A14 | solute carrier family 2 member 14 | 2 | 2 | ||||||||
MIRT468466 | SET | SET nuclear proto-oncogene | 2 | 4 | ||||||||
MIRT468725 | SDC4 | syndecan 4 | 2 | 2 | ||||||||
MIRT468784 | SCAMP5 | secretory carrier membrane protein 5 | 2 | 2 | ||||||||
MIRT469154 | RNF121 | ring finger protein 121 | 2 | 2 | ||||||||
MIRT473436 | MDM4 | MDM4, p53 regulator | 2 | 2 | ||||||||
MIRT473636 | MARK2 | microtubule affinity regulating kinase 2 | 2 | 2 | ||||||||
MIRT474242 | LCLAT1 | lysocardiolipin acyltransferase 1 | 2 | 2 | ||||||||
MIRT474654 | KLF13 | Kruppel like factor 13 | 2 | 2 | ||||||||
MIRT475384 | ICOSLG | inducible T-cell costimulator ligand | 2 | 2 | ||||||||
MIRT475400 | ICMT | isoprenylcysteine carboxyl methyltransferase | 2 | 4 | ||||||||
MIRT476369 | GIGYF1 | GRB10 interacting GYF protein 1 | 2 | 2 | ||||||||
MIRT478017 | DNAJC8 | DnaJ heat shock protein family (Hsp40) member C8 | 2 | 2 | ||||||||
MIRT478459 | DAB2 | DAB2, clathrin adaptor protein | 2 | 2 | ||||||||
MIRT478791 | CRTC2 | CREB regulated transcription coactivator 2 | 2 | 2 | ||||||||
MIRT478952 | COX15 | COX15, cytochrome c oxidase assembly homolog | 2 | 2 | ||||||||
MIRT480412 | C19orf47 | chromosome 19 open reading frame 47 | 2 | 2 | ||||||||
MIRT481455 | ARRB2 | arrestin beta 2 | 2 | 2 | ||||||||
MIRT481556 | ARL10 | ADP ribosylation factor like GTPase 10 | 2 | 2 | ||||||||
MIRT481740 | APH1A | aph-1 homolog A, gamma-secretase subunit | 2 | 2 | ||||||||
MIRT483592 | SLC26A9 | solute carrier family 26 member 9 | 2 | 2 | ||||||||
MIRT484423 | SNX19 | sorting nexin 19 | 2 | 2 | ||||||||
MIRT484727 | HOXB8 | homeobox B8 | 2 | 6 | ||||||||
MIRT487419 | CACNB1 | calcium voltage-gated channel auxiliary subunit beta 1 | 2 | 2 | ||||||||
MIRT487622 | C20orf96 | chromosome 20 open reading frame 96 | 2 | 2 | ||||||||
MIRT488048 | PABPC1L2B | poly(A) binding protein cytoplasmic 1 like 2B | 2 | 2 | ||||||||
MIRT488064 | PABPC1L2A | poly(A) binding protein cytoplasmic 1 like 2A | 2 | 2 | ||||||||
MIRT488587 | ST7L | suppression of tumorigenicity 7 like | 2 | 2 | ||||||||
MIRT488696 | NAT9 | N-acetyltransferase 9 (putative) | 2 | 2 | ||||||||
MIRT489175 | ANKRD45 | ankyrin repeat domain 45 | 2 | 4 | ||||||||
MIRT490435 | MYL9 | myosin light chain 9 | 2 | 2 | ||||||||
MIRT490452 | GLUD1 | glutamate dehydrogenase 1 | 2 | 2 | ||||||||
MIRT490704 | FSTL4 | follistatin like 4 | 2 | 2 | ||||||||
MIRT491038 | ALPK3 | alpha kinase 3 | 2 | 2 | ||||||||
MIRT491249 | HCN2 | hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 | 2 | 2 | ||||||||
MIRT491632 | SEMA4G | semaphorin 4G | 2 | 2 | ||||||||
MIRT492491 | RAPGEF1 | Rap guanine nucleotide exchange factor 1 | 2 | 2 | ||||||||
MIRT492506 | RANBP10 | RAN binding protein 10 | 2 | 4 | ||||||||
MIRT493917 | FAM127B | retrotransposon Gag like 8A | 2 | 4 | ||||||||
MIRT494012 | DUSP9 | dual specificity phosphatase 9 | 2 | 2 | ||||||||
MIRT499188 | RBPJL | recombination signal binding protein for immunoglobulin kappa J region like | 2 | 2 | ||||||||
MIRT499813 | LONRF3 | LON peptidase N-terminal domain and ring finger 3 | 2 | 2 | ||||||||
MIRT501837 | NCOA2 | nuclear receptor coactivator 2 | 2 | 2 | ||||||||
MIRT504067 | KCTD12 | potassium channel tetramerization domain containing 12 | 2 | 4 | ||||||||
MIRT505313 | TOR1AIP2 | torsin 1A interacting protein 2 | 2 | 2 | ||||||||
MIRT511829 | H2AFX | H2A histone family member X | 2 | 4 | ||||||||
MIRT515497 | GTF2F1 | general transcription factor IIF subunit 1 | 2 | 2 | ||||||||
MIRT518629 | NONO | non-POU domain containing octamer binding | 2 | 2 | ||||||||
MIRT519774 | ZNF354B | zinc finger protein 354B | 2 | 8 | ||||||||
MIRT521806 | POM121C | POM121 transmembrane nucleoporin C | 2 | 2 | ||||||||
MIRT522621 | MAP7D1 | MAP7 domain containing 1 | 2 | 4 | ||||||||
MIRT532803 | CLDN11 | claudin 11 | 2 | 2 | ||||||||
MIRT533783 | TMEM119 | transmembrane protein 119 | 2 | 2 | ||||||||
MIRT536433 | KMT2B | lysine methyltransferase 2B | 2 | 6 | ||||||||
MIRT538700 | CASP16 | caspase 16, pseudogene | 2 | 4 | ||||||||
MIRT544603 | DCAF5 | DDB1 and CUL4 associated factor 5 | 2 | 2 | ||||||||
MIRT556730 | KLHL15 | kelch like family member 15 | 2 | 4 | ||||||||
MIRT560587 | LCE1B | late cornified envelope 1B | 2 | 2 | ||||||||
MIRT560617 | ANKRD36 | ankyrin repeat domain 36 | 2 | 2 | ||||||||
MIRT564348 | AKR1B10 | aldo-keto reductase family 1 member B10 | 2 | 2 | ||||||||
MIRT568925 | SMCR8 | Smith-Magenis syndrome chromosome region, candidate 8 | 2 | 2 | ||||||||
MIRT570946 | CPE | carboxypeptidase E | 2 | 2 | ||||||||
MIRT571235 | SCAMP4 | secretory carrier membrane protein 4 | 2 | 2 | ||||||||
MIRT573805 | FRMPD4 | FERM and PDZ domain containing 4 | 2 | 2 | ||||||||
MIRT574149 | MARVELD1 | MARVEL domain containing 1 | 2 | 2 | ||||||||
MIRT575772 | Tnfrsf10b | tumor necrosis factor receptor superfamily, member 10b | 2 | 2 | ||||||||
MIRT576154 | Hmox1 | heme oxygenase 1 | 2 | 2 | ||||||||
MIRT611312 | CA8 | carbonic anhydrase 8 | 2 | 4 | ||||||||
MIRT615891 | MT1A | metallothionein 1A | 2 | 2 | ||||||||
MIRT669589 | AK2 | adenylate kinase 2 | 2 | 2 | ||||||||
MIRT687186 | PRKAR1A | protein kinase cAMP-dependent type I regulatory subunit alpha | 2 | 2 | ||||||||
MIRT692711 | MEAF6 | MYST/Esa1 associated factor 6 | 2 | 2 | ||||||||
MIRT701346 | NR4A3 | nuclear receptor subfamily 4 group A member 3 | 2 | 2 | ||||||||
MIRT701997 | MIER3 | MIER family member 3 | 2 | 2 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|